IMMX Immix Biopharma, Inc. Net earnings per share growth this year

IMMX (immixbio.com) - company brandmark

The strategic goal of Immix Biopharma, Inc. (IMMX) is to overcome stringent FDA controls and patent barriers within CAR-T therapy. The annual EPS trend demonstrates progress on this path, where 19.80 determines the current status of the parameter. However, the absence of commercial revenue and reliance on external financing, coupled with zero pricing power, create significant obstacles for market capitalization growth.

Immix Biopharma (IMMX): Net earnings per share growth this year from 07/04/2022 to 11/15/2026

Analytical breakdowns and data insights for company immixbio.com (IMMX)

- current quotes and average value forecast:
Summary company analysis:IMMX (Immix Biopharma)
Brand item of Immix Biopharma, Inc.

This indicator measures the dynamics of net income per share compared to the same period last year. For Immix Biopharma, Inc. (IMMX), low capital expenditures resulting from outsourced trials directly impact the volatility of this metric. By analyzing the annual percentage growth of net income per share via GURU.Markets, an investor assesses the efficiency of the operating model. The fluctuations on the chart reflect the speed of monetizing scientific developments, which allows for an assessment of the company's capital stability.

Key competitors

IBRX - Expected net earnings per share growth this year|Earnings per share growth in current year immunocore.com|Net earnings per share growth this year januxrx.com (JANX)|Earnings per share growth in current year Arcus Biosciences Inc (RCUS)|Net earnings per share growth this year Zymeworks Corp ZYME|Tango Therapeutics Inc - Net earnings per share growth this year|Earnings growth in current year Iovance Corp IOVA|IMTX - Earnings per share growth in current year|XNCR (xencor.com) - Earnings per share growth this year|Compass Therapeutics Corp (CMPX) - Earnings per share growth in current year|Earnings per share growth rate in current year Replimune Corp (REPL)|Net earnings per share growth this year LYEL|IPHA - Net earnings per share change in current year|Net earnings per share growth this year PYXS (Pyxis Oncology, Inc.)|Net earnings per one share growth for the current year CGEN|Earnings growth in current year IOBT (IO Biotech)|Earnings per share increase in current year STRO|minktherapeutics.com - Earnings growth in current year|Earnings per share growth rate in current year Werewolf Therapeutics, Inc.|ALX Oncology (ALXO) - Earnings per share growth in current year|cuebiopharma.com (CUE) - Earnings growth in current year|PDSB (PDS Biotechnology Corp) - Earnings growth in current year|Earnings growth in current year sonnetbio.com|Earnings per share growth in current year MAIA Biotechnology, Inc. (MAIA)|LIMN: Earnings per share trend in current year|LAVA Therapeutics - Net earnings per share growth this year|nextcure.com (NXTC) - Earnings per share growth rate in current year|LPTX - Earnings per share growth in current year|Expected net earnings per share growth this year Intensity Therapeutics, Inc. INTS|SNSE: Earnings growth in current year|Synthetic Biologics - Earnings per share increase in current year|GRTS (Gritstone bio) - Earnings growth in current year|KA (Kineta, Inc.) - Net earnings per one share growth for the current year|Earnings growth in current year NEXI|Turnstone Biologics Corp - Earnings per share growth this year|Earnings growth in current year VCNX (Vaccinex Inc)|Harpoon Therapeutics Corp (HARP) - Earnings per share growth rate in current year